Stephen V Liu: Early ctDNA Dynamics in SCLC Show Prognostic Value in TAZMAN Trial
Stephen V Liu, Director of Thoracic Oncology, Chief, Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Carmela Ciardullo et al. published in Clinical Cancer Research:
“Early ctDNA dynamics in SCLC from the TAZMAN trial (n=31) at Clinical Cancer Research. Baseline ctDNA yielded somatic alterations in 96% of patients. ctDNA clearance had positive prognostic value and changes anticipated relapse before imaging. Possible pharmacodynamic marker?”
Title: Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer
Authors: Carmela Ciardullo, Luis Tobalina, T. Hedley Carr, Philip Szekeres, Silvija Kraljevic, Lauren Averett Byers, Giulia Fabbri
You can read the Full Article on Clinical Cancer Research.
More posts featuring Stephen V Liu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023